|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Alkaptonuria | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Ochronosis | |||||
| 3 | More general conditions related to this trial | ||||
| Amino Acid Metabolism, Inborn Errors | |||||
| Genetic Diseases, Inborn | |||||
| Metabolic Diseases | |||||
| Metabolism, Inborn Errors | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| Nitisinone (NTBC) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Nitisinone | |||||
| 6 | More general drug interventions related to this trial | ||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| 7 | Sponsors listed in this trial | ||||
| National Human Genome Research Institute (NHGRI) | |||||